EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors

Endoscopic Ultrasound-guided Fine-needle Injection for Multiple Endocrine Neoplasia Type 1-related Pancreatic Neuroendocrine Tumors: a Prospective Multicenter Study

The present study aims to evaluate the feasibility, safety and efficacy of EUS-FNI for MEN1-related pNETs

The management of multiple endocrine neoplasia type 1 (MEN1-1)-related pancreatic neuroendocrine tumors (pNETs) remains controversial. In general, surgical resection is currently the first-line therapy for MEN1-1-related pNETs. However, the surgical resection of pNETs is conditional for specific patients, and the incidence of postoperative adverse events is still high. Recently, several studies have demonstrated that endoscopic ultrasonography (EUS)-guided fine-needle injection (EUS-FNI) with ethanol or lauromacrogol may provide an alternative to surgical resection of pNETs. Nevertheless, their sample size was relatively small and conclusions were drawn based on short-term results. Therefore, a multicenter prospective study is being performed to further access the efficacy and safety of EUS-FNI for MEN1-1-related pNETs.

Multiple endocrine neoplasia type 1, Pancreatic neuroendocrine tumor, Endoscopic ultrasonography-guided fine-needle injection, Ablation

Diagnostic evaluation for suspected MEN1-1-related pNETs is conducted by cytology or immunohistochemistry and genetic testing. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol/ lauromacrogol under the guidance of EUS was injected into the tumor The volume of ethanol/ lauromacrogol is administrated based on the tumor size.

Inclusion Criteria: Patients with MEN1-1-related pNETs are evaluated by histopathology and genetic testing. Patients who refuse surgery. Patients who have given their fully informed consent. Exclusion Criteria: Patients who are not suitable for the endoscopic procedure. Patients who have blood coagulation dysfunction, mental disorders, mild or severe cardiorespiratory.